SCHEMBL3846985

SCHEMBL3846985

NC(=O)CC(=O)c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 1/20 0.60
NPC1 O15118 2/20 0.57
PTPN1 P18031 1/20 0.57
RAB9A P51151 1/20 0.57
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
ALOX12 P18054 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HTR7 P34969 1/20 0.50
AGTR1 P30556 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
ALDH1A1 P00352 1/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
HSD11B1 P28845 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3856158 0.98 PLOD2 (0.58) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL24209439 0.89 PARP10 (0.50) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL2491432 0.86 PLOD2 (0.69) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL4720570 0.85 PLOD2 (0.58) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL30305722 0.83 PLOD2 (0.56) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL6458755 0.81 NPC1 (0.67) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL10789236 0.80 TSHR (0.55) NPC1PTPN1RAB9AMEN1MAPT
SCHEMBL30114978 0.80 PLOD2 (0.62) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL904555 0.80 PLOD2 (0.62) PLOD2NPC1PTPN1RAB9AMEN1
SCHEMBL27745056 0.80 BLM (0.61) NPC1PTPN1RAB9AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113527205-B Preparation method of blonanserin intermediate 湖南省湘中制药有限公司 2022-04-01 CN claimed
CN-110526867-B Method for efficiently preparing blonanserin intermediate 湖南省湘中制药有限公司 2021-12-03 CN claimed
CN-113527205-A Preparation method of blonanserin intermediate 湖南省湘中制药有限公司 2021-10-22 CN claimed
CN-110526867-A A method of efficiently preparing blonanserin intermediate HUNAN XIANGZHONG PHARMACEUTICAL CO LTD 2019-12-03 CN claimed
CN-104447551-A Method for preparing blonanserin CHEER FINE PHARMACEUTICAL ANHUI CO LTD 2015-03-25 CN claimed
CN-101747273-B Preparing method of blonanserin intermediate ZHEJIANG HUAHAI PHARM CO LTD 2012-03-07 CN claimed
CN-102030707-A Method for preparing Blonanserin intermediate SHENZHEN WANHE PHARMACEUTICAL CO LTD 2011-04-27 CN claimed
CN-101747273-A Preparing method of blonanserin intermediate SHANGHAI INST PHARM INDUSTRY 2010-06-23 CN claimed
CN-119161299-A Preparation method of anti-schizophrenia drug blonanserin 湖南大学 2024-12-20 CN disclosed
CN-119143672-A Method for synthesizing blonanserin by taking ammonium iodide as nitrogen source 湖南大学 2024-12-17 CN disclosed
CN-113527205-B Preparation method of blonanserin intermediate 湖南省湘中制药有限公司 2022-04-01 CN disclosed
CN-113527205-B Preparation method of blonanserin intermediate 湖南省湘中制药有限公司 2022-04-01 CN disclosed
CN-110526867-B Method for efficiently preparing blonanserin intermediate 湖南省湘中制药有限公司 2021-12-03 CN disclosed
CN-110526867-B Method for efficiently preparing blonanserin intermediate 湖南省湘中制药有限公司 2021-12-03 CN disclosed
EP-2048142-A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof Eisai R&D Management Co., Ltd. (JP) 2009-04-15 EP disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 PLOD2 4356/4885NPC1 4248/4885PTPN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.